NGM Bio is a research-driven, clinical-stage biopharmaceutical company that has generated a promising pipeline of therapeutics addressing cardio-metabolic and liver diseases. Our deep expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving the development of transformational medicines that dramatically improve human health.
NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. Our initial R&D focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer.
NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.
Working with our strategic partners Merck and MedImmune, NGM Bio is working to develop a portfolio of high-impact therapeutics for underserved patient populations.
To date, we have generated a pipeline that includes:
NGM Biopharmaceuticals Hiring Statement
We are a clinical-stage biotech company with a passion to improve the lives of those struggling with disease. We seek like-minded colleagues to join our creative and dynamic discovery and development organization.
In particular, we seek team members with “fire in their belly,” with a strong desire to bring medicines to patients. We look for individuals who:
-Are forward and creative thinkers
-Are willing to push the boundaries of knowledge and science
-Have superb ability to collaborate and build strong
-Thrive on challenges and can carry multiple priorities
Mr. Rieflin joined NGM as Chief Executive Officer in 2010 and brings over 20 years of industry experience to the company. Most recently, he was President of XenoPort, Inc. (NASDAQ: XNPT). Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves on the Board of Directors of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), FLX Bio, Inc. and XenoPort. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
Prior to joining NGM in 2014, Mr. Jonker was the Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG) and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, he was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Dr. Chen is the Company's Founder, and has served as a member of the board of directors and as the Chief Scientific Officer since January 2008. He was also NGM's President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company's global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen's pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.
Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.
Prior to joining NGM in 2010, Dr. DePaoli was CMO at InteKrin Therapeutics. In this role he oversaw global development of INT131, a PPARg modulator, through a successful End of Phase 2 meeting with the FDA. He brings to NGM more than 20 years of experience as a clinician and translational researcher in diabetes, obesity and metabolic disease. Dr. DePaoli trained in Clinical and Molecular Endocrinology at the University of Chicago and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and translational research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute which led him to join Amgen in 1998 to champion the development of their cardiometabolic disease portfolio. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine leptin (Myalept). At Amgen, he also led a broad array of cardiometabolic, muscle and bone programs with a focus on translating novel pathways into the clinic. These pathways included: RANK Ligand (now Prolia and Xgeva), PCSK9 (Evolocumab), 11 Beta HSD-1, Myostatin, IL-1 receptor, Calcium Sensing Receptor (Sensipar), PPAR-gamma modulation, DPP-4 and MCH-R1. Dr. DePaoli also maintains a clinical endocrinology practice at the William Sansum Diabetes Center.
Dr. Trombley joined NGM as head of Business Development in 2011 and became our Vice President, Chief Operating Officer in 2015. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. (NASDAQ: XNPT), where her responsibilities also included strategic and portfolio planning in addition to various out-licensing projects. Prior to XenoPort, she was a Senior Engagement Manager at McKinsey & Company, where she advised pharmaceutical and medical device clients on strategic, commercial and operational issues. She received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from MIT.
Dr. Woodhouse joined NGM in 2015 from Goldman Sachs where he was a managing director and co-head of U.S. biotechnology investment banking. As a member of Goldman's healthcare investment banking group for nearly 13 years in both the New York and San Francisco offices, his responsibilities included corporate finance and mergers and acquisitions advice for the biotechnology, specialty pharma and diagnostics industries. In this capacity, he advised on several billion in equity and equity-linked financings as well as over $90 billion in M&A transactions.
Prior to Goldman Sachs, Dr. Woodhouse worked in various business development and research roles at Dynavax and Amgen. He graduated, with highest honors, from UC Santa Barbara, with a B.A. in Pharmacology. He also earned a Ph.D. in Molecular Pharmacology from Stanford University School of Medicine and an M.B.A. from the Tuck School of Business at Dartmouth.
Scientific Advisory Board
Michael S. Brown
Dr. Brown is Paul J. Thomas Professor of Molecular Genetics and Director of the Erik Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical School in Dallas. Together with his long-time colleague, Dr. Joseph L. Goldstein, he discovered the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. They showed that mutations in this receptor cause Familial Hypercholesterolemia, a disorder that leads to premature heart attacks in one out of every 500 people in most populations. They have received many awards for this work, including the Nobel Prize for Medicine or Physiology (1985), the Albert D. Lasker Prize in Basic Medical Research (1985) and the U.S. National Medal of Science (1988). He is also a member of the National Academy of Sciences, the Institute of Medicine, Royal Society (London), the Association of American Physicians and the American Society for Clinical Investigation.
Prof. Fischbach is an Assistant Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF and a member of the California Institute for Quantitative Biosciences (QB3). Prof. Fischbach is a leading expert in the identification and characterization of natural products from the microbiome. He received his Ph.D. in chemistry from Harvard in 2007, and spent two years as an independent fellow at Massachusetts General Hospital before coming to UCSF. Prof. Fischbach is a recipient of the NIH Director's New Innovator Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, and the Young Investigator Grant for Probiotics Research from the Global Probiotics Council.
K. Christopher Garcia
Prof. Garcia is a Professor of Molecular and Cellular Physiology, and of Structural Biology at the Stanford University School of Medicine. He received his Ph.D. in biophysics from the Johns Hopkins University and completed post-doctoral work at Genentech and at the Scripps Research Institute before joining Stanford University in 1999. He was elected to the National Academy of Sciences in 2012 and is also an investigator with the Howard Hughes Medical Institute since 2005. Prof. Garcia is a leading scientist studying the structural biology of cytokine receptor recognition and activation, and probing cytokine signaling mechanisms using protein engineering. His research has identified new paradigms for recognition and activation of a variety of receptors that play critical roles in autoimmunity, cancer, neural growth and repair, and blood pressure regulation.
Joseph L. Goldstein
Dr. Goldstein is Regental Professor and Chairman of the Department of Molecular Genetics at the University of Texas Southwestern Medical School in Dallas, and he also holds the Paul J. Thomas Chair in Medicine and the Julie and Louis A. Beecherl Distinguished Chair in Biomedical Science. He and his long-time colleague, Dr. Michael S. Brown, have worked together for the last 40 years on the genetics and regulation of cholesterol metabolism. Their discovery of the LDL receptor as the major molecule regulating cholesterol metabolism and its genetic disruption in the human disease Familial Hypercholesterolemia have been recognized by their receipt of numerous awards, including the Nobel Prize in Physiology or Medicine (1985), the Albert D. Lasker Award in Basic Medical Research (1985) and the U.S. National Medal of Science (1988). He is also a member of the National Academy of Sciences, Institute of Medicine, Royal Society (London), the Association of American Physicians and the American Philosophical Society.
Robert D. Schreiber
Prof. Schreiber is the Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology at Washington University School of Medicine in St. Louis. He is also co-leader of the Tumor Immunology Program of Washington University’s Siteman Comprehensive Cancer Center, Director of the Washington University Center for Human Immunology and Immunotherapy Programs and an Associate Director of the Scientific Advisory Council to the Cancer Research Institute. His career has focused on elucidating the biochemistry and molecular cell biology of cytokines and defining the role they play in promoting immune responses to cancer. Prof. Schreiber’s work has led to a generalized appreciation of the profound effect of immunity on developing tumors and has contributed critical conceptual and practical support to the fields of tumor immunology and cancer immunotherapy. Recently, he and his colleagues have pioneered the use of genomics approaches to define the antigenic targets of cancer immuneediting and elucidate the mechanisms that underlie the process. Prof. Schreiber was inducted into the American Academy of Arts and Sciences in 2010 and the National Academy of Sciences in 2013.
I have been working at NGM Biopharmaceuticals full-time
NGM Bio has strong and innovative research efforts. A place where people have high ambitions to make discoveries leading to novel therapies. A lot of great energy and very nice colleagues.
NGM Bio is still a growing company, you needs to be flexible to meet challenges as the company is growing and changing.
I applied through an employee referral. I interviewed at NGM Biopharmaceuticals (San Francisco, CA).
In total the phone interview might have been 4-5 hours. The initial session was about 2 hours filled by 45 mins to 1 hour blocks. Honestly, I'm not sure why the phone interview lasted so long.
Let us know if we're missing any workplace or industry recognition –